AbbVie Inc. $ABBV Stock: Marble Harbor Investment Counsel LLC Grows Position

Marble Harbor Investment Counsel LLC increased its position in AbbVie Inc. (NYSE:ABBV – Free Report) by 14.4% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 203,038 shares of the company’s stock after acquiring an additional 25,609 shares during the quarter. AbbVie accounts for about 4.9% of Marble Harbor Investment Counsel LLC’s investment portfolio, making the stock its 3rd biggest holding. Marble Harbor Investment Counsel LLC’s holdings in AbbVie were worth $51,055,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. Allworth Financial LP increased its position in shares of AbbVie by 113.1% during the 3rd quarter. Allworth Financial LP now owns 474,678 shares of the company’s stock valued at $124,171,000 after purchasing an additional 251,927 shares during the last quarter. Fisher Asset Management LLC boosted its holdings in shares of AbbVie by 252.6% in the third quarter. Fisher Asset Management LLC now owns 33,489,421 shares of the company’s stock worth $8,760,498,000 after buying an additional 23,991,451 shares during the last quarter. SVB Wealth LLC boosted its holdings in shares of AbbVie by 7.6% in the third quarter. SVB Wealth LLC now owns 59,646 shares of the company’s stock worth $14,856,000 after buying an additional 4,214 shares during the last quarter. Legacy Trust boosted its holdings in shares of AbbVie by 5.1% in the third quarter. Legacy Trust now owns 8,263 shares of the company’s stock worth $2,162,000 after buying an additional 402 shares during the last quarter. Finally, Ariadne Wealth Management LP grew its position in AbbVie by 3.0% during the third quarter. Ariadne Wealth Management LP now owns 5,730 shares of the company’s stock valued at $1,499,000 after buying an additional 165 shares during the period. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie News Roundup

Here’s some of the latest news about ABBV:

  • Positive Sentiment: AbbVie’s immunology sales rose 16.6% in the third quarter, with Skyrizi and Rinvoq growth more than offsetting Humira’s decline. The performance has supported higher 2026 sales expectations and strengthens the case that newer drugs can sustain growth. How Did AbbVie’s Immunology Franchise Fare in Q3?
  • Neutral Sentiment: A Crohn’s disease study update drew coverage describing its likely near-term stock impact as limited; it does not appear to materially change the immediate investment outlook. AbbVie Crohn’s Disease Study Update
  • Negative Sentiment: Executive Vice President Jeffrey Stewart sold 40,619 shares for about $11.9 million, reducing his direct holdings by 32.81%. Insider sales can weigh on sentiment, though the filing does not explain the reason for the transaction. SEC Form 4 filing

Insider Buying and Selling at AbbVie

In related news, EVP Jeffrey Stewart sold 40,619 shares of the company’s stock in a transaction on Monday, November 9th. The shares were sold at an average price of $293.60, for a total value of $11,925,738.40. Following the completion of the transaction, the executive vice president owned 83,171 shares of the company’s stock, valued at approximately $24,419,005.60. This represents a 32.81% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 0.06% of the company’s stock.

Wall Street Analyst Weigh In

ABBV has been the subject of a number of research reports. Piper Sandler upped their target price on shares of AbbVie from $298.00 to $303.00 and gave the company an “overweight” rating in a report on Thursday, August 20th. Oppenheimer increased their price target on shares of AbbVie from $244.00 to $258.00 and gave the stock a “neutral” rating in a research report on Monday, August 3rd. BMO Capital Markets set a $315.00 price target on shares of AbbVie in a research note on Wednesday, November 4th. Bank of America reiterated a “buy” rating on shares of AbbVie in a research note on Tuesday, September 8th. Finally, Canaccord Genuity Group boosted their price objective on shares of AbbVie from $290.00 to $338.00 and gave the company a “buy” rating in a research report on Monday, November 2nd. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $297.46.

View Our Latest Report on AbbVie

AbbVie Trading Down 0.1%

NYSE ABBV opened at $294.75 on Friday. AbbVie Inc. has a 12 month low of $190.75 and a 12 month high of $302.93. The stock has a market cap of $521.01 billion, a price-to-earnings ratio of 50.73, a PEG ratio of 1.34 and a beta of 0.20. The company’s 50 day moving average is $274.82 and its two-hundred day moving average is $240.55.

AbbVie (NYSE:ABBV – Get Free Report) last posted its quarterly earnings results on Friday, October 30th. The company reported $3.82 earnings per share for the quarter, topping analysts’ consensus estimates of $3.73 by $0.09. The business had revenue of $17.40 billion during the quarter, compared to analyst estimates of $17.32 billion. AbbVie had a net margin of 15.67% and a negative return on equity of 450.55%. The company’s revenue was up 10.3% on a year-over-year basis. During the same period in the prior year, the business posted $1.86 earnings per share. Sell-side analysts forecast that AbbVie Inc. will post 13.98 EPS for the current year.

AbbVie Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, February 16th. Investors of record on Friday, January 15th will be paid a dividend of $1.82 per share. This is a positive change from AbbVie’s previous quarterly dividend of $1.73. The ex-dividend date is Friday, January 15th. This represents a $7.28 dividend on an annualized basis and a dividend yield of 2.5%. AbbVie’s dividend payout ratio is presently 119.10%.

About AbbVie

(Free Report)

AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.

Recommended Stories

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.